DOCSLIB.ORG

Introduction to Microperimetry and Its Use in Analysis of Geographic Atrophy in Age-Related Macular Degeneration

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Introduction to Microperimetry and Its Use in Analysis of Geographic Atrophy in Age-Related Macular Degeneration REVIEW CURRENT OPINION Introduction to microperimetry and its use in analysis of geographic atrophy in age-related macular degeneration Mostafa Hanout, Nicholas Horan, and Diana V. Do Purpose of review This article discusses recent advances in the fundus-guided perimetry (microperimetry) and its utilization in evaluation and monitoring of patients with geographic atrophy. Recent findings Although best-corrected visual acuity has been gold standard in clinical practice for decades, it does not provide an entire assessment of visual function that determines daily activity and quality of life of a patient. Furthermore, psychophysical tests, including low-luminance visual acuity, reading speed, and contrast sensitivity, cannot be used to quantify retinal sensitivity or detect pattern of retinal dysfunction. Microperimetry provides a true evaluation of visual function by offering fundus-controlled testing through eye-tracking technology that allows for structural and functional correlation and test–retest reliability for the same test point. Furthermore, it enables precise assessment of location and stability of fixation. Recent research has shown microperimetry to be more representative of the macular function in macular diseases. Summary Microperimetry is currently the clinical investigation of choice to assess residual visual functions and functional vision in macular degenerative diseases, especially geographic atrophy. There is an increasing popularity to employ microperimetry in clinical trials investigating new treatments for geographic atrophy, as well as other macular degenerative diseases, as a reliable functional outcome measure. Keywords fixation, geographic atrophy, microperimetry, preferred retinal locus, retinal sensitivity INTRODUCTION low-luminance visual acuity among others. How- The advances in retinal imaging technologies ever, none of these testing parameters has proved have revolutionized contemporary diagnostic in ability to quantify retinal sensitivity or detect ophthalmology and enabled early detection along pattern of retinal dysfunction [2–4]. For many years, with documentation of treatment results of retinal conventional static perimetry has been established diseases. Precise clinical evaluation of retinal, as an essential clinical tool for quantification of especially macular involving, diseases necessitates visual field and retinal threshold especially in glau- correlating both the morphological and the func- coma and neuro-ophthalmological disorders. None- tional aspects. The latter is more self-appreciated by theless, it is often inadequate for accurate evaluation patients, as major visual tasks determining the qual- of macular function, especially with troublesome ity of life of patient grossly depend on it [1]. For eccentric or unsteady fixation, or both [1,5,6]. decades, best-corrected visual acuity has been the gold standard in clinical practice; however, it does not represent an entire assessment of macular func- Stanley M. Truhlsen Eye Institute, University of Nebraska Medical Center, tion. There are several puzzling presentations by Omaha, Nebraska, USA patients whose visual function is inconsistent with Correspondence to Diana V. Do, MD, Stanley M. Truhlsen Eye Institute, visual acuity such as patients with paracentral mac- University of Nebraska Medical Center, 985540 Nebraska Medical ular lesions sparing the foveal center. Several psy- Center, Omaha, NE 68198-5540, USA. Tel: +1 402 559 4276; chophysical tests have been utilized, in addition to fax: +1 402 559 5514; e-mail: [email protected] visual acuity, to evaluate macular function such as Curr Opin Ophthalmol 2015, 26:149–156 Amsler grid, contrast sensitivity, reading speed, and DOI:10.1097/ICU.0000000000000153 1040-8738 Copyright ß 2015 Wolters Kluwer Health, Inc. All rights reserved. www.co-ophthalmology.com Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved. Retinal, vitreous and macular disorders fundus observation during examination [9]. The KEY POINTS main challenge was that the bright light necessary Best-corrected visual acuity, psychophysical tests, and for adequate retinal illumination will interfere with conventional perimetry, albeit useful, do not fulfill the functional testing. With the advent of scanning desired comprehensive assessment of macular function laser ophthalmoscope (SLO), the infrared light in macular degenerative diseases. source permitted simultaneous observation of the fundus during examination and led to introduction Residual visual function has more impact on the patient daily activity and quality of life. of the first microperimeter (SLO 101, Rodenstock, Ottobrunn, Germany) in the year 1982 [9,10]. Microperimetry is currently the clinical investigation of Shortcomings of this device included semiauto- choice to assess residual visual functions and functional mated stimulus presentation and lack of eye tracker vision in macular degenerative diseases, especially to compensate for ocular movements; the device is geographic atrophy. no longer available in the market. These limitations Microperimetry offers fundus-controlled testing of retinal have been overcome by Nidek MP-1 (Nidek Tech- sensitivity through eye-tracking technology that allows nologies, Padova, Italy) that was introduced to the for structural and functional correlation and test–retest market in 2003 as the first fundus perimeter with eye reliability for the same test point. Furthermore, it tracker that compensates for eye movements based enables precise assessment of location and stability of fixation. on an initial frame. With these new features in Nidek MP-1, exact correlation between retinal dis- Recent trends may call for incorporating microperimetry order and functional defects was rendered possible as a standard functional outcome measure in clinical even in eyes with poor or unstable fixation trials of geographic atrophy. [11,12&,13,14]. Thereafter, in 2006, a more recent Spectral OCT/SLO microperimeter was introduced to the market by OPKO/OTI (OPKO Instrumenta- More recently, microperimetry has effectively tion, Miami, Florida, USA) that incorporated spec- provided fundus-correlated functional testing, tral optical coherence tomography (OCT) with test–retest reliability for the same test point, precise microperimetry, offering an additional advantage assessment of the location and stability of fixation, of correlating retinal dysfunction with the corre- and compensation for ocular movements. By incor- sponding ultrastructural finding as shown by porating these features, microperimetry has become OCT. The technology was later transferred to Optos the clinical investigation of choice to assess residual Inc., and the device was named Optos OCT/SLO visual functions and functional vision in macular (Optos, Dunfermline, Scotland, UK). Optos OCT/ diseases [7,8]. SLO is the only US Food and Drug Adminis- This article covers basic concepts and recent tration-approved microperimeter; it received advances in microperimetry, common market- 510(k) clearance in 2013 [3,15–18]. Macular Integ- available microperimeters, and the steadily growing rity Assessment (MAIA; CenterVue, Padova, Italy) role of microperimetry in clinical evaluation and was the latest instrument to reach the market in monitoring of macular diseases, particularly, geo- 2009, garnished with high-frequency eye tracker graphic atrophy. Latest research observations repor- and a line confocal SLO [6,7]. Table 1 summarizes ted during the review period are also summarized. key differences between the three commercially available microperimeters. EVOLUTION OF MICROPERIMETRY According to many experts in the field, ‘micro- CLINICAL APPLICATIONS OF perimetry’ is not the most accurate naming for this MICROPERIMETRY ocular imaging technology, given the currently used Indeed, microperimetry surpasses conventional peri- examination parameters of stimulus size ranging metry in several aspects in evaluation of retinal sen- from Goldman I to V, and examination field sitivity in macular diseases [19]. One fundamental of up to 158–208 from the foveal center. Rather, advantage of microperimetry is the real-time tracking ‘fundus-correlated perimetry’ or ‘fundus-guided of the fundus throughout perimetric testing. This perimetry’ are considered more accurate names. allows perimetric examination of patients with For sake of simplicity, we used the term ‘micro- eccentric or unstable fixation. The ability of regis- perimetry’ throughout the article [5,6]. The need tration of macular sensitivity results on digital fundus to achieve correlation between clinically apparent photograph allows for functional and structural retinal disorder and functional testing urged the correlation [6]. Furthermore, in conventional peri- demand to design a perimetry device that enables metry, the stimulus is projected on a screen in front 150 www.co-ophthalmology.com Volume 26 Number 3 May 2015 Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved. Introduction to microperimetry and its role in analysis of geographic atrophy Hanout et al. Table 1. Summary of commercially available microperimeters Nidek MP-1 Optos OCT/SLO MAIA Manufacturer Nidek Technologies, Optos, Dunfermline, CenterVue, Padova, Italy Padova, Italy Scotland, UK Year of arrival to the market 2003 2006 2009 Features of incorporated fundus imaging Infrared and digital color SLO black and white SLO black and white Microperimetric examination parameters Size of the of the microperimetry testing field 458 29.78 368 Fixation assessment
Load more

Recommended publications
  • Climate Change and Human Health: Risks and Responses
    Climate change and human health RISKS AND RESPONSES Editors A.J. McMichael The Australian National University, Canberra, Australia D.H. Campbell-Lendrum London School of Hygiene and Tropical Medicine, London, United Kingdom C.F. Corvalán World Health Organization, Geneva, Switzerland K.L. Ebi World Health Organization Regional Office for Europe, European Centre for Environment and Health, Rome, Italy A.K. Githeko Kenya Medical Research Institute, Kisumu, Kenya J.D. Scheraga US Environmental Protection Agency, Washington, DC, USA A. Woodward University of Otago, Wellington, New Zealand WORLD HEALTH ORGANIZATION GENEVA 2003 WHO Library Cataloguing-in-Publication Data Climate change and human health : risks and responses / editors : A. J. McMichael . [et al.] 1.Climate 2.Greenhouse effect 3.Natural disasters 4.Disease transmission 5.Ultraviolet rays—adverse effects 6.Risk assessment I.McMichael, Anthony J. ISBN 92 4 156248 X (NLM classification: WA 30) ©World Health Organization 2003 All rights reserved. Publications of the World Health Organization can be obtained from Marketing and Dis- semination, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel: +41 22 791 2476; fax: +41 22 791 4857; email: [email protected]). Requests for permission to reproduce or translate WHO publications—whether for sale or for noncommercial distribution—should be addressed to Publications, at the above address (fax: +41 22 791 4806; email: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries.
    [Show full text]
  • OCT WORLD Pushing the Boundaries of Optical Coherence Tomography Technology from Our Chair, Edward G
    visionDuke Eye Center 2016 It’s an OCT WORLD pushing the boundaries of optical coherence tomography technology From our Chair, Edward G. Buckley, MD 2 10 24 2016 VOLUME 32 hat an amazing first year as Chairman of the Department of Ophthalmology. There have been so many exciting events over the past year. 2 50 Years of Duke Ophthalmology 1 Message from the Chair W . The Department celebrated its 50th anniversary 24 Development News 4 Hudson Building at Duke Eye Center in 2015. 36 Faculty Awards and News COVER STORY . A long-planned dream came true with the opening of our state-of-the-art clinical facility, the Hudson 10 It’s an OCT World 38 New Faculty Building at Duke Eye Center. 16 Innovative Macular Surgery 40 Administration, Faculty and Staff . Our faculty won awards, had clinical breakthroughs, and made advances in several 20 Duke Eye Center by the Numbers areas. While ophthalmology has been an important part of 22 The Art of Reconstructive Surgery Duke Medical Center since the 1940’s, the stand-alone 26 Pediatric Glaucoma Patient Sets Out to Help Others department was established in 1965. With the appointment and vision of Joseph A. C. Wadsworth, MD, the first 01 27 Expanding Ocular Oncology chairman of the Department of Ophthalmology, Duke Eye Center was established and initiated the three-building 28 Center for Macular Diseases Studying New Treatments for AMD campus that we have today. I hope you enjoy reading more about our history and the timeline of events over the last 30 New Partnership Accelerates Research on Glaucoma Genetics 50 years.
    [Show full text]
  • Microcurrent Stimulation in the Treatment of Dry and Wet Macular Degeneration
    Journal name: Clinical Ophthalmology Article Designation: Original Research Year: 2015 Volume: 9 Clinical Ophthalmology Dovepress Running head verso: Chaikin et al Running head recto: Microcurrent stimulation for macular degeneration treatment open access to scientific and medical research DOI: http://dx.doi.org/10.2147/OPTH.S92296 Open Access Full Text Article ORIGINAL R ESEARC H Microcurrent stimulation in the treatment of dry and wet macular degeneration Laurie Chaikin1 Purpose: To determine the safety and efficacy of the application of transcutaneous Kellen Kashiwa2 (transpalpebral) microcurrent stimulation to slow progression of dry and wet macular degenera- Michael Bennet2 tion or improve vision in dry and wet macular degeneration. George Papastergiou3 Methods: Seventeen patients aged between 67 and 95 years with an average age of 83 years Walter Gregory4 were selected to participate in the study over a period of 3 months in two eye care centers. There were 25 eyes with dry age-related macular degeneration (DAMD) and six eyes with wet 1Private practice, Alameda, CA, USA; 2Retina Institute of Hawaii, age-related macular degeneration (WAMD). Frequency-specific microcurrent stimulation was Honolulu, HI, USA; 3California Retinal applied in a transpalpebral manner, using two programmable dual channel microcurrent units Associates, San Diego, CA, USA; delivering pulsed microcurrent at 150 MA for 35 minutes once a week. The frequency pairs 4Clinical Trials Research Unit, Faculty of Medicine and Health, University of selected were based on targeting tissues, which are typically affected by the disease combined Leeds, Leeds, UK with frequencies that target disease processes. Early Treatment Diabetic Retinopathy Study or Snellen visual acuity (VA) was measured before and after each treatment session.
    [Show full text]
  • The Primate Model for Understanding and Restoring Vision
    The primate model for understanding and restoring vision Serge Picauda,1, Deniz Dalkaraa,1, Katia Marazovaa, Olivier Goureaua, Botond Roskab,c,d,2, and José-Alain Sahela,e,f,g,2 aInstitut de la Vision, INSERM, CNRS, Sorbonne Université, F-75012 Paris, France; bInstitute of Molecular and Clinical Ophthalmology Basel, CH-4031 Basel, Switzerland; cFaculty of Medicine, University of Basel, 4056 Basel, Switzerland; dFriedrich Miescher Institute, 4058 Basel, Switzerland; eDepartment of Ophthalmology, The University of Pittsburgh School of Medicine, Pittsburgh, PA 15213; fINSERM-Centre d’Investigation Clinique 1423, Centre Hospitalier National d’Ophtalmologie des Quinze-Vingts, F-75012 Paris, France; and gDépartement d’Ophtalmologie, Fondation Ophtalmologique Rothschild, F-75019 Paris, France Edited by Tony Movshon, New York University, New York, NY, and approved October 18, 2019 (received for review July 8, 2019) Retinal degenerative diseases caused by photoreceptor cell death provide highly responsive and reliable models for in-depth are major causes of irreversible vision loss. As only primates have a functional studies. Furthermore, brain-imaging studies de- macula, the nonhuman primate (NHP) models have a crucial role scribing visual cortex activity aid our understanding of the vi- not only in revealing biological mechanisms underlying high-acuity sual system and its functions and also serve as important tools vision but also in the development of therapies. Successful trans- for studying the brain (5–8). lation of basic research findings into clinical trials and, moreover, approval of the first therapies for blinding inherited and age- Uniqueness of the Primate Model for Human Vision related retinal dystrophies has been reported in recent years.
    [Show full text]
  • 2020-SEI-AR Redact Edit.Pdf
    1 1 SIMPLY WORLD CLASS The Viterbi Family Department of Ophthalmology and the Shiley Eye Institute at UC San Diego offers treatment across all areas of eye care. Our world class clinicians, surgeons, scientists and staff are dedicated to excellence and providing the best possible patient care to prevent, treat and cure eye diseases. Our research is at the forefront of developing new methods to diagnose and treat eye diseases and disorders. In addition to educating the leaders of tomorrow, we are committed to serving the San Diego and global community. 2 2 C O N T E N T S 10 16 LETTERS 4 EXECUTIVE COMMITTEE 7 YEAR IN REVIEW 9 COVID-19 10 HIGHLIGHTS OF THE YEAR 20 21 36 FACULTY 46 RESIDENTS & FELLOWS 59 SIMPLY WORLD CLASS EDUCATION 62 PUBLICATIONS & GRANTS 72 GIVING 86 FRONT COVER IMAGE: Transmission electron microscopic image of an isolate from the first U.S. case of COVID-19, formerly known as 2019-nCoV. The spherical viral particles, colorized blue, contain cross-section through the viral genome, seen as black dots. 3 3 Letter from the Chancellor Dear Friends, In this especially challenging year, tional vision care and expertise. This report is filled with news UC San Diego is innovating to and stories from the past year that illustrate a holistic ap- meet the needs of our students proach to improving vision health through patient-centered and patients and adjusting to our care, leading-edge collaborative research, and community new reality so we can maintain our outreach. We are incredibly grateful for your contributions to- pursuit of groundbreaking discov- ward these efforts, and for the lasting impact you are making eries.
    [Show full text]
  • Ucla Stein Eye Institute Vision-Science Campus
    SPRING 2020 VOLUME 38 NUMBER 1 UCLA STEIN EYE INSTITUTE EYEVISION-SCIENCE CAMPUS LETTER FROM THE CHAIR To have 20/20 vision is to see clearly, and for the UCLA Department of Ophthalmology, the year 2020 heralds in both a new decade and a focus on our mission to preserve sight and end avoidable blindness. Research is core to this aim, and in this issue of EYE Magazine, we highlight basic scientists in the UCLA Stein Eye Institute’s Vision Science Division who are studying the fundamental mechanisms of visual function and using that knowledge to define, identify, and ultimately cure eye disease. Clinical research trials are also underway at Stein Eye and the Doheny Eye Centers UCLA, and include the first in-human trial of autologous cultivated limbal cell therapy to treat limbal stem cell deficiency, a blinding corneal disease; evaluation of an investiga- tional medication to treat graft-versus-host disease, a potentially EYE MAGAZINE is a publication of the serious complication after transplant procedures; comparison of UCLA Stein Eye Institute drug-delivery systems to determine which is most effective for DIRECTOR treatment of diabetic macular edema; and analysis of regenerative Bartly J. Mondino, MD strategies for treatment of age-related macular degeneration. MANAGING EDITOR UCLA Department of Ophthalmology award-winning researchers Tina-Marie Gauthier conduct investigations of depth and magnitude, and the Depart- c/o Stein Eye Institute 100 Stein Plaza, UCLA ment has taken a central role in transforming vision science as a Los Angeles, California 90095–7000 powerful platform for discovery. I thank our faculty and staff for their [email protected] sight-saving endeavors, and I thank you, our donors and friends, for PUBLICATION COMMITTEE supporting our scientific explorations.
    [Show full text]
  • Springer Clinical Medicine Preview Top Frontlist October – December 2013
    ABC springer.com Springer Clinical Medicine Preview Top Frontlist October – December 2013 FOURTH QUARTER 2013 springer.com New Publications at the Forefront of Research & Development Dear reader, This catalog is a special selection of new book publications from Springer in the fourth quarter of 2013. It highlights the titles most likely to interest specialists working in the professional field or in academia. You will find the international authorship and high quality contributions you have come to expect from the Springer brand in every title. Please show this catalog to your buyers and acquisition staff. It is a premier and most authoritative source of new print book titles from Springer. We offer you a wide range of publication types – from contributed volumes focusing on current trends, to handbooks for in-depth research, to textbooks for graduate students. If you are looking for something very specific, go to our online catalog at springer.com and search among the 83,000 English books in print by keyword. The Advanced Search makes it easy to define any scientific subject you have. You can even download a catalog just like this one with your own personal selection – completely free of charge! We hope you will enjoy browsing through our new titles and make your selection today! With best wishes, Matthew Giannotti Product Manager, Trade Marketing P.S. Register on springer.com for automatic New Book Alerts by subject. If you register as a bookseller, you will also receive the monthly Bookseller Alert that announces every new title by subject in the Springer NEWS catalog. Legend Book with online Book CD-ROM Textbook files/update with CD-ROM Book DVD Set with DVD springer.com Medicine | Anaesthesiology B.
    [Show full text]
  • Thursday May 2, 2019
    Thursday May 2, 2019 ARVO Annual Meeting Registration Main Lobby 7am – 1pm ARVO 2020 —Baltimore Kickoff Reception/ All Posters 2 – 3pm Beckman-Argyros Award Lecture 3:15 –4:15pm ARVO/Alcon Closing Keynote 9 ARVO Ballroom 4:30 – 6pm APRIL 28 – MAY 2 VANCOUVER, B.C. 341 Thursday, May 2 – Symposia, papers, workshops/SIGs and lectures Thursday, May 2 – Posters Time Session Title Location Time Session Title Board No. 8 – 10am 501 The gut-eye axis: Emerging roles of the microbiome in ocular immunity and diseases West 212-214 8 – 9:45am 503 Glaucoma: biochemistry and molecular biology, genomics and proteomics [BI] A0001 - A0030 [RC, IM, RE, CL, CO, BI] 504 Proteomics, lipidomics, metabolomics and systems biology [BI] A0031 - A0043 502 The single cell revolution: Novel insights and applications for single cell RNA West 217-219 505 Lens Biochemistry and Cell Biology [LE] A0044 - A0062 sequencing in eye research [IM, AP, BI, CO, PH, RC, VN, GEN] 506 Retina/RPE new drugs, mechanism of action, and toxicity [PH] A0099 - A0119 10:15am – 528 Mechanistic analysis of ocular morphogenesis, growth and disease [AP] East 1 12 noon 507 Blood flow, Ischemia/reperfusion, hypoxia and oxidative stress [PH] A0120 - A0140 529 AMD and Antiangiogenic agents [PH] East 2/3 508 Vitreoretinal Surgery, Novel Techniques and Clinical Applications [RE] A0191 - A0250 530 Advances in Retinal Gene Therapy and Stem Cells [RE] East 8&15 509 Proliferative Vitreoretinopathy- Translational Studies [RE] A0251 - A0261 531 Biology of Retinal Neurons [RC] East 11/12 510 Myopia and Refractive Error [CL] A0314 - A0358 532 Ocular microbiology and vaccines [IM] East Ballroom A 511 Molecular mechanisms and anatomical changes in experimental myopia [AP, CL] A0359 - A0395 533 Retinal Surgery and PVR [RE] East Ballroom B 512 Vision Assessment & Performance.
    [Show full text]
  • Pluripotent Stem Cell Therapy for Retinal Diseases
    1279 Review Article on Novel Tools and Therapies for Ocular Regeneration Page 1 of 17 Pluripotent stem cell therapy for retinal diseases Ishrat Ahmed1, Robert J. Johnston Jr2, Mandeep S. Singh1 1Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA; 2Department of Biology, Johns Hopkins University, Baltimore, MD, USA Contributions: (I) Conception and design: I Ahmed, MS Singh; (II) Administrative support: MS Singh; (III) Provision of study material or patients: None; (IV) Collection and assembly of data: None; (V) Data analysis and interpretation: None; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors. Correspondence to: Mandeep S. Singh, MD, PhD. Wilmer Eye Institute, Johns Hopkins Hospital, 600 N Wolfe St, Baltimore, MD 21287, USA. Email: [email protected]. Abstract: Pluripotent stem cells (PSCs), which include human embryonic stem cells (hESCs) and induced pluripotent stem cell (iPSC), have been used to study development of disease processes, and as potential therapies in multiple organ systems. In recent years, there has been increasing interest in the use of PSC- based transplantation to treat disorders of the retina in which retinal cells have been functionally damaged or lost through degeneration. The retina, which consists of neuronal tissue, provides an excellent system to test the therapeutic utility of PSC-based transplantation due to its accessibility and the availability of high- resolution imaging technology to evaluate effects. Preclinical trials in animal models of retinal diseases have shown improvement in visual outcomes following subretinal transplantation of PSC-derived photoreceptors or retinal pigment epithelium (RPE) cells. This review focuses on preclinical studies and clinical trials exploring the use of PSCs for retinal diseases.
    [Show full text]
  • Subretinal Transplantation of Embryonic Stem Cell– Derived Retinal Pigment Epithelium for the Treatment of Macular Degeneration: an Assessment at 4 Years
    Special Issue Subretinal Transplantation of Embryonic Stem Cell– Derived Retinal Pigment Epithelium for the Treatment of Macular Degeneration: An Assessment at 4 Years Steven D. Schwartz,1 Gavin Tan,1,2 Hamid Hosseini,1 and Aaron Nagiel1 1Retina Division, Stein Eye Institute, University of California Los Angeles Geffen School of Medicine, Los Angeles, California, United States 2Singapore Eye Research Institute, Singapore National Eye Centre, Singapore Correspondence: Steven D. Advanced macular degeneration is an important cause of vision loss in the United States with Schwartz, Retina Division, Stein Eye over 2 million people affected by the disease. Despite substantial progress in the development Institute, UCLA Geffen School of of new therapies for wet AMD, the severe visual impairment associated with geographic Medicine, Los Angeles, CA 90095, atrophy in dry AMD or Stargardt disease remains untreatable. Recently, two phase I/II studies USA; [email protected]. involving 18 patients with these diseases have demonstrated that it is possible to safely implant human embryonic stem cell–derived RPE (hESC-RPE) in an attempt to rescue Submitted: November 23, 2015 photoreceptors and visual function. The anatomical and functional results are encouraging, Accepted: March 24, 2016 with more than half of treated patients experiencing sustained improvements in visual acuity Citation: Schwartz SD, Tan G, Hosseini and demonstrating evidence of possible cellular engraftment. However, any conclusions H, Nagiel A. Subretinal transplantation remain tempered by the relatively short follow-up time, lack of a formal control group, poor of embryonic stem cell-derived retinal initial visual acuity, and small number of patients. Aside from an instance of postoperative pigment epithelium for the treatment infectious endophthalmitis, no adverse events related to the cell therapy, such as of macular degeneration: an assess- hyperproliferation, tumorigenicity, or rejection-related inflammation were noted in this ment at 4 years.
    [Show full text]
  • Microperimetry
    ARCH SOC ESP OFTALMOL 2006; 81: 183-186 EDITORIAL MICROPERIMETRY MICROPERIMETRÍA MIDENA E1 Clinical investigation of retinal disorders has rential light sensitivity or retinal threshold). The both a morphological and a functional approach. principle of microperimetry rests on the possibility The functional approach is probably more relevant to see —in real time— the retina under examination when looking at a retinal disease (before and/or (by infrared light) and to project a defined light sti- after treatment) from the patient’s point of view. mulus over an individual, selected location. Becau- When testing retinal function with psychophysical se light projection is just related to previously selec- tests we are more related to visual experience than ted anatomical landmarks, and it is independent of with any other functional method (1). Visual acuity fixation and any other eye movement, the examiner is still considered the gold standard in clinical prac- obtains the functional response of the selected area tice, but it does not entirely reflect functional vision (2). The characteristics of fixation (location and sta- (which describes the impact of sight on quality of bility) are easily and exactly quantified with micro- life activities). The ubiquity and success of evalua- perimetry. Scanning laser ophthalmoscope (SLO) ting retinal sensitivity by static (and kinetic) peri- microperimetry was the first technique which allo- metry demonstrates that quantification of retinal wed to obtain a fundus-related sensitivity map, in threshold is
    [Show full text]
  • Microperimetry and Optical Coherence Tomography Changes in Type-1 Diabetes Mellitus Without Retinopathy
    diagnostics Article Microperimetry and Optical Coherence Tomography Changes in Type-1 Diabetes Mellitus without Retinopathy Elvira Orduna-Hospital 1,2 , Judit Otero-Rodríguez 2, Lorena Perdices 1, Ana Sánchez-Cano 1,2 , Ana Boned-Murillo 1,3 , Javier Acha 1,4 and Isabel Pinilla 1,3,* 1 Aragon Institute for Health Research (IIS Aragon), 50009 Zaragoza, Spain; [email protected] (E.O.-H.); [email protected] (L.P.); [email protected] (A.S.-C.); [email protected] (A.B.-M.); [email protected] (J.A.) 2 Department of Applied Physics, University of Zaragoza, 50009 Zaragoza, Spain; [email protected] 3 Department of Ophthalmology, Lozano Blesa University Hospital, 50009 Zaragoza, Spain 4 Department of Endocrinology, Miguel Servet University Hospital, 50009 Zaragoza, Spain * Correspondence: [email protected]; Tel.: +34-696-808-295 Abstract: Background: We aimed to measure and correlate inner retinal layer (IRL) thickness and macular sensitivity by optical coherence tomography (OCT) and by microperimetry, respectively, in type 1 diabetes mellitus patients (DM1) without diabetic retinopathy (DR). Methods: Fifty-one DM1 patients and 81 age-matched healthy subjects underwent measurement of the axial length (AL), retinal thickness in the macular ETDRS areas by swept source (SS)-OCT and macular sensitivity by microperimeter. Results: The total retinal and IRL thicknesses were thicker in the DM1 group (p < 0.05) in practically all ETDRS areas, and they had a generalized decrease in sensitivity (p < 0.05) in 9 areas between both groups. There was a significant negative correlation between retinal sensitivity and age in all areas and in visual acuity (VA) in 5 out of the 9 areas for DM1 patients.
    [Show full text]